International pharmaceutical firm Eli Lilly will set up a manufacturing base in South Korea for “Mounjaro,” a glucagon-like peptide-1 (GLP-1) class weight problems therapy. That is anticipated to turn out to be the primary case of a GLP-1 class weight problems therapy being manufactured within the nation.
Underneath a deal to be introduced later this 12 months, SK Biotek, a Korean subsidiary of SK Pharmteco, a worldwide CDMO operation wholly owned by SK Inc., is anticipated to supply the energetic pharmaceutical ingredient (API), whereas a separate accomplice will take cost of completed product manufacturing. Eli Lilly is anticipated to formally announce the plan inside the 12 months.
SK Pharmteco is developing its fifth and sixth crops, large-scale peptide uncooked materials manufacturing amenities, on the Myeonghak Industrial Advanced in Sejong, North Chungcheong province, by its subsidiary SK Biotek. The plant has a complete flooring space of 26,410 sq. meters throughout one basement degree and 5 flooring above floor, and features a uncooked supplies manufacturing constructing, a utility constructing geared up with manufacturing course of infrastructure, and high quality management (QC) and U.S. present Good Manufacturing Apply (cGMP) take a look at manufacturing amenities.
After completion in June subsequent 12 months, the plant is scheduled to start full-scale operation by the tip of the 12 months and instantly begin annual peptide manufacturing on the dimensions of tens of tons. SK Pharmteco is reviewing manufacturing for Eli Lilly provide at Plant 4 as properly to arrange for future order enlargement. It’s reported that staff from Eli Lilly headquarters lately visited SK’s Sejong plant and performed tools inspections for 2 weeks. Whereas SK Pharmteco has not issued an official place, trade watchers anticipate the CDMO contract to progress easily.
On the completed product manufacturing stage, Peptron, which possesses long-acting peptide injectable expertise, is thought to be a robust candidate. The corporate plans to construct a brand new cGMP plant within the Osong Superior Medical Advanced in Cheongju with the capability to supply as much as 10 million vials of long-acting injectables yearly.
